γδT细胞为基础的抗肿瘤免疫治疗研究进展  

Research progress of γδT cell-based immunotherapy

作　　者：邱福铭[1] 李忠朋[1] 黄建[1] 

机构地区：[1]浙江大学医学院附属第二医院肿瘤科,浙江杭州310009

出　　处：《浙江大学学报（医学版）》2010年第4期424-429,共6页Journal of Zhejiang University(Medical Sciences)

基　　金：浙江省卫生高层次创新人才培养工程专项基金资助项目;浙江省151人才工程专项基金资助项目

摘　　要：γδT细胞是介于获得性免疫与天然免疫之间的特殊免疫细胞类型,具有抗原特异性识别功能而无MHC限制。目前,已从外周血及肿瘤等组织中分离到Vγ9Vδ2T细胞,并发现其γδTCR与非肽磷酸抗原结合可激活该细胞,在IL-2刺激下出现扩增,并在体外呈现出杀伤多种肿瘤的功能。动物实验发现,激活的Vγ9Vδ2T细胞回输可抑制淋巴瘤、乳腺癌、恶性黑色素瘤等肿瘤生长。以Vγ9Vδ2T细胞为基础的免疫治疗已在晚期肺癌、肾癌、前列腺癌等Ⅰ期临床研究中已显示出良好效果。文中从γδT细胞的抗原识别与活化、体外研究、体内研究和临床研究几个方面,对γδT细胞为基础的抗肿瘤免疫治疗进行综述。γδT cells are considered as linkage between innate and adaptive immune response,which recognize specific antigen without MHC-restriction.Vγ9Vδ2T cells,isolated from peripheral blood and tumor tissue,can be activated by non-peptide phosphoantigen through binding to its γδTCR and proliferate under IL-2 stimulation.It has been shown that Vγ9Vδ2T cells possess anticancer activity against several types of tumor in vitro,as well as inhibit the growth of lymphoma,breast cancer and malignant melanoma in vivo.The phase Ⅰ clinical trial of the application of Vγ9Vδ2T cells in treatment of lung cancer,renal cancer and prostate cancer demonstrated promising results.This review summarizes the recent advances in antigen recognition and activation of γδT cells,and the γδT cell-based immunotherapy for cancer treatment.

关 键 词：肿瘤/治疗 抗原 肿瘤/遗传学 T淋巴细胞 ΓΔT细胞 免疫疗法 抗肿瘤 Vγ9Vδ2T细胞 

分 类 号：R730.51[医药卫生—肿瘤]